Abstract

Since we last reviewed the drug treatment of Parkinson's disease in 1995,1 several new drugs have been licensed for its treatment, more is known about the use of levodopa plus selegiline, and new surgical techniques have been developed. Here we review these new developments and consider how they affect patient management.